Poland· PL-100233014
Imipenem/Cilastatin Kabi
A imipenem and cilastatin product containing imipenemum + cilastatinum, registered in Poland by Fresenius Kabi Polska Sp. z o.o.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Imipenem and cilastatin is registered in 12 of 19 countries.
Countries holding a registration under ATC J01DH51 (imipenem and cilastatin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Imipenem and cilastatin · ATC J01DH51
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Imipenemum + Cilastatinum
- Manufacturer
- Fresenius Kabi Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- J01DH51
- ATC class
- Imipenem and cilastatin
- Defined daily dose
- 2 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909990805600
- gtin05909990928071
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for imipenem and cilastatin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Imipenem and cilastatin · interactions on record
1 record
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under J01DH51
Imipenem and cilastatin, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f2c2b16a-23ab-488b-ab7d-d27713c68da1 GET /v1/drugs/f2c2b16a-23ab-488b-ab7d-d27713c68da1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "500 mg + 500 mg",
"packaging": "05909990805600 ¦ Rp ¦ 60594\n10 fiol. 1000 mg\n05909990928071 ¦ Rp ¦ 71898\n10 butelek 1000 mg",
"substance": "Imipenemum 500 mg + Cilastatinum 500 mg",
"common_name": "Imipenemum + Cilastatinum",
"pl_product_id": "100233014",
"pozwolenie_nr": "17381",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about imipenem and cilastatin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.